WithdrawnNot Applicable

Memantine Monotherapy for Executive Dysfunction and ADHD

0Started 2013-07

Plain-language summary

This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Memantine HC1, brand name Namenda) in the treatment of executive function deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD). After screening procedures, memantine is prescribed in randomized, double-blind fashion (equal chance of medication or placebo) for 12 weeks. The investigators hypothesize that memantine hydrochloride will prove to be an effective, safe, and well-tolerated agent for the treatment of EFDs in individuals with ADHD interested in non-stimulant medications.

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male and female adults ages 18-45 years;
✓. a diagnosis of DSM-IV \[78\] ADHD-combined type
✓. a score of at least 20 on the AISRS (a score of 20 in the AISRS identifies subjects with at least moderate severity of symptoms);
✓. a BRIEF-A Global Executive Composite T-score of \>6; and
✓. proficiency in English. -

What they're measuring

Brief-A Self-Report

Timeframe: Baseline to 12 weeks

Trial details

NCT IDNCT01844427

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-03

View on ClinicalTrials.gov More ADHD trials